Recurrence of febrile convulsions and phenobarbital treatment.
Explore the source record for details and available documents.
Child↗
Biomedical subjects
B Rothe
Publications and source records attributed to B Rothe.
[Immunoscintigraphy and SPECT in patients with pancreatic cancer].
Encouraged by reports on immunoscintigraphy of colorectal carcinomas and by the results of our own immunohistochemical and immunoscintigraphic studies in nude mice with transplanted pancreatic carcinoma, we studied the diagnostic potential of immunoscintigraphy with a cocktail of 131I-labeled monoclonal antibodies against the tumor markers CA 19-9 and CEA in 21 patients with pancreatic cancer disease. The results were compared with those of 10 patients suffering from colorectal tumors, 2 cases with bile duct carcinoma and 1 with gastric cancer. Planar scintigraphy with 2-4 views was done repeatedly within 6 days after i.v infusion of 2 mCi of the antibody cocktail. SPECT was performed 3-4 days p.i., recently at 1 or 2 days, too. Primary tumors and metastases in the upper abdominal parts were more difficult to detect and to localise in comparison to colorectal cancer in the lower parts of the abdomen, because of relatively high tracer accumulation in kidneys, liver and spleen. Tumor enhancement in planar scintigrams was, in most cases, not recognized prior to 5 or 6 days p.i., but by SPECT 3 days p.i. or even earlier. Localisation and topographic determination were much easier and more frequent with SPECT, so that tumor detection became more reliable and sensitive. Large tumors could be detected in some cases without tumor marker concentrations in serum being elevated. Immunoscintigraphy of pancreatic carcinomas and of other cancer manifestations in the upper abdomen up to now seems to be of limited diagnostic value, the techniques involved need to be improved.
Adult↗
Functional properties of deoxycorticosterone and spironolactone: molecular characterization and effects on sleep-endocrine activity.
Adrenal steroid hormones are capable of interfering with a variety of behavioral phenomena including sleep. The mechanisms appear to involve effects at the cell membrane as well as nuclear actions mediated by intracellular mineralo- and glucocorticosteroid receptors (MR and GR). We employed the MR agonist deoxycorticosterone (DOC) and the MR antagonist spironolactone (SP) to study the role of MRs in the regulation of human sleep. We also tested whether the effects of DOC upon the sleep EEG and nocturnal hormone secretion (growth hormone and cortisol) are compatible with those predicted for its major metabolite tetrahydro-DOC (THDOC): electrophysiological and animal experiments had suggested that THDOC would act as a hypnotic via positive modulation of the GABAA receptor. Because neither DOC nor SP affected the sleep EEG substantially, the involvement of MRs in the regulation of sleep needs further study. The sleep-endocrine data showed a suppressive effect of DOC upon plasma cortisol concentrations and an earlier occurrence of nocturnal GH maxima, which can be plausibly explained by GR or sigma receptor-mediated effects. Molecular characterization of DOC and SP confirmed a relatively strong effect of DOC upon transactivation via MR and no effect of SP on the GR-mediated transcription rate. In addition, the possibility that a low dose of the mineralocorticoid DOC may serve as a prodrug for the potential hypnotic THDOC is not supported by the current data.
Adult↗
Effects of an ACTH/MSH(4-9) analog (HOE 427) on the sleep EEG and nocturnal hormonal secretion in humans.
The synthetic ACTH/MSH(4-9) analog HOE 427 ("ebiratide"), which is behaviorally the most potent ACTH-derived peptide but which is devoid of endocrine activity, was administered intravenously in a pulsatile mode 4 times (120 micrograms each) at 2200, 2300, 2400 and 0100 to study its effect on the sleep EEG and on concomitant hormonal secretion of cortisol and growth hormone. In comparison to placebo, the peptide produced signs of general activation associated with specific deteriorating effects on the quality of sleep. Sleep onset latency and intermittent wakefulness were increased, slow wave sleep was reduced, but only during the first 3 hours of the sleep period. The nocturnal secretory patterns of cortisol and growth hormone were unaffected by HOE 427. These effects are different from those reported in similar studies in which corticotropin-releasing hormone (CRH) was applied in humans, and they suggest that peripherally administered neuropeptides have specific nonendocrine behavioral effects.
Adrenocorticotropic Hormone↗